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ABSTRACT 
 
To prepare the way for using the isotopically labelled SABRE hyperpolarised 4,6-d2-
nicotinamide as an MRI agent in humans we have performed an in-vivo study to 
measure its pharmacokinetics in the plasma of healthy rats after intravenous and oral 
administration. Male Han Wistar rats were dosed with either 4,6-d2-nicotinamide or the 
corresponding control, non-labelled nicotinamide, and plasma samples were obtained 
at eight time points for up to 24 hours after administration. Pharmacokinetic 
parameters were determined from agent concentration-versus-time data for both 4,6-
d2-nicotinamide and nicotinamide. 4,6-d2-nicotinamide proved to be  well tolerated 
regardless of route of administration at the concentrations used (20, 80 and 120 
mg/kg). Pharmacokinetic parameters were similar after oral and intravenous 
administration and similar to those obtained for nicotinamide. Analysis of nicotinamide 
plasma concentrations after dosing 4,6-d2-nicotinamide intravenously demonstrates a 
reversible exchange of endogenous nicotinamide by this labelled agent over the time-
course of our assays. Supported by a large body of evidence for the safety of 
nicotinamide when dosed orally in humans, we conclude that 4,6-d2-nicotinamide can 
also be safely administered intravenously, which will provide significant benefit when 
using this agent for planned imaging studies in humans. 
 
1. Introduction 
Over the last few decades Magnetic Resonance Imaging (MRI) has evolved to 
become an extremely important technique that allows researchers to obtain 
anatomical, functional and metabolic information. However, even after this 
tremendous success, its applicability is limited due to low sensitivity and high cost. The 
low sensitivity is derived from the fact that nuclei possess little intrinsic magnetisation 
and interact weakly with a magnetic field. Dynamic nuclear polarization (DNP) is now 
an established technique for dramatically increasing the sensitivity of magnetic 
resonance imaging and spectroscopy for the study of in-vivo metabolism 
(Kurhanewicz et al., 2011; Gallagher et al., 2011). Using pyruvate as a 
hyperpolarization agent, DNP has demonstrated that detailed clinical MRI images can 
be obtained in humans (Grist et al., 2019; Daniels et al., 2016). We have sought to 
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overcome the low sensitivity problem by developing similarly highly visible agents 
through a method of hyperpolarisation called SABRE (Adams et al., 2009). SABRE¶V
rapidity and potentially low cast mean it too has the potential to revolutionise clinical 
MRI, and related MR methods by improving the strength of the detected response by 
over four orders of magnitude from its normal level as found on a routine 1.5T clinical 
MRI system (Rayner et al., 2017; Duckett et al., 2013). SABRE reflects a novel 
approach that does not change the chemical identity of the agent it hyperpolarizes but 
insteady equilibrates polarization between p-H2 and the selected agent through 
binding to an iridium centre (Adams et al., 2009) in a novel form of catalysis. With this 
sensitivity gain, SABRE hyperpolarization of 1H, 13C, 15N, 31P atoms (Iali et al., 2018; 
Roy et al., 2018; Olaru et al., 2017) in labelled drugs or agents is expected to radically 
enhance their future detection by MRI and allow imaging of metabolic and physiologic 
processes of substrates in vivo. It may also enable in vivo nano-chemistry and 
metabolomics, and decreases the time needed to observe a metabolite concentration 
change (Viale, 2010; Kurhanewicz et al., 2011).  
We have chemically developed nicotinamide (NA) using NMR assessment as 
a SABRE agent for future MRI applications. NA belongs to the niacin family of 
compounds and is a common nutrient. It is also described as belonging to a class of 
compounds called histone deacetylase (HDAC) inhibitors, which have been shown to 
SURWHFWWKHFHQWUDOQHUYRXVV\VWHPLQURGHQWPRGHOVRI3DUNLQVRQ¶VDQG+XQWLQJWRQ¶V
diseases (Didonna et al., 2015). Clinical trials are currently underway to learn whether 
+'$&LQKLELWRUVKHOS$/6DQG+XQWLQJWRQ¶VSDWLents (Wild et al., 2014). Our SABRE 
agent, 4,6-d2-nicotinamide (d2-NA), has the same chemical structure as NA except 
that two protons at positions 4 and 6 on the aromatic ring have been replaced by 
deuterium (Rayner et al., 2017). Though numerous publications have discussed the 
advantages and disadvantages of deuterated drugs (Liu et al., 2017; Gant, 2014; 
Katsnelson, 2013; Sanderson et al, 2009; Foster, 1985) and several companies focus 
on the use of deuterated drugs for various conditions, we use deuteration solely to 
enhance the SABRE hyperpolarization properties of NA. The deuterium positions are 
magnetically silent and serve to focus magnetization on the two remaining aromatic 
protons. The ability of SABRE to hyperpolarize protons, as in d2-NA, makes it 
applicable as a method to make agents for use in all hospital MRI scanners. One of 
the benefits of deuterium labelling is that the magnetic longitudinal relaxation time of 
d2-NA is considerably extended when compared to NA (Rayner et al., 2017). 
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One factor that was important in selecting NA is that it is an intrinsically safe 
clinical agent that has already been used in pharmacological doses over many years 
with a low incidence of side effects and toxicity (Final Report of the Safety Assessment 
of Niacinamide and Niacin. 2005). Importantly, previous literature reports provide 
considerable evidence that NA reflects a safe therapy to use when given at adult doses 
of up to 10 g/day orally (Knip, 2000) and is commonly used in clinical trials at oral (PO) 
GRVHVRI g/day in humans for various indications. Doses (up to 6 g/day) have been 
used in combination with radiotherapy (Dragovic et al., 1995). The pharmacokinetics 
of NA are known to be dependent on dose, species, sex and route of administration. 
Safe doses in rats have previously been characterized: 750 mg/kg for subcutaneous 
injection and 1000 mg/kg for IP injection (Ayouba et al., 1999)  Furthermore, 
intravenous (IV) doses of 750 mg/kg in rat models of stroke (Sakakibara et al., 2000) 
have been used. An in vitro cytotoxicity study demonstrated that it is possible to create 
a biocompatible SABRE bolus of d2-NA and that deuteration of NA does not increase 
the toxicity compared to the NA (Manoharan et al, 2018). 
We are now seeking to progress d2-NA to first-in-human exploratory MR 
imaging studies, where it is anticipated that this agent will be used intravenously as a 
bolus injection to observe perfusion in the heart or brain, for example. In order to pave 
the way for using d2-NA we intend to conduct two in-vivo preclinical studies: a PK study 
and a single dose toxicity study in rats. At sub-therapeutic doses, guided by a body of 
clinical data for NA in humans and current regulatory guidelines, only rodent data may 
be required to support the use of d2-NA in humans. We report here the results of the 
first of these whereby the pharmacokinetics of d2-NA in the plasma of healthy rats 
after PO and IV administration was measured. Data describing IV administration of NA 
in human is limited and there is no corresponding information known for d2-NA.  The 
pharmacokinetics study of d2-NA is required to predict its efficacy and the duration of 
its effects, especially in comparison to NA, and to provide supportive data on the 
mechanisms of drug action, to predict side-effects and for the extrapolation of results 
from laboratory animals to man. In this study, we used sub-therapeutic doses between 
20 and 120 mg/kg in rats. The main objective is to measure plasma concentrations of 
d2-NA following IV and PO administration and to compare these to the 
pharmacokinetics of NA.  
 
2. Materials and Methods 
I. Linnik et al.                           European Journal of Pharmaceutical Sciences XXX (2019) XXX±XXX 
5 
 
This is a non-regulatory study for which a claim of GLP compliance is not been made. 
However, the laboratory procedures used were consistent with International 
Standards of GLP. 
2.1  Animals. Fifteen male Han Wistar rats were obtained from Charles River 
Laboratories, Margate, UK. Animals were all in the target weight range of 163 to 
215 g at dosing. Diet was removed at the end of the working day prior to each dose 
occasion, and returned 4 hours after dosing.  
2.2  Agents used. Both d2-NA and NA were formulated by dissolving appropriate 
amounts of each in 0.9% physiological saline and were assessed visually for 
complete dissolution. No cloudy suspension or particles were visible (Table 1). 
2.3 Experimental design. Each animal received a single administration (Table 2). PO 
doses were administered by gavage at a nominal dose volume of 5 mL/kg. IV 
doses were administered via a lateral tail vein, at a nominal dose volume of 
2 mL/kg, as a bolus injection. Body weights were recorded the day after arrival and 
before dose administration and used for calculation of doses. Samples of blood 
(nominally 150 µL) were collected from the jugular vein of each animal. For PO 
dosing this was done at 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose. For IV 
dosing this was at 0.016, 0.083, 0.5, 1, 2, 4, 8 and 24 hours post dose. The actual 
blood collection time was used in the subsequent PK data analysis. Blood was 
collected into tubes containing the K2EDTA anticoagulant and stored at room 
temperature. Blood was centrifuged (1500 g, 10 minutes, 4°C) to produce plasma 
for analysis and residual blood cells were discarded. 
2.4 Blood plasma assay for d2-NA and NA. Initial NA concentration quantification  
revealed an endogenous NA background peak during calibration, the intensity of 
which is consistent with a level of approximately 50 ng/mL. Concentrations of d2-
NA and NA were subsequently determined by the now qualified LC-MS/MS method 
of Table 3 which involved the following steps: 
1. Transfer of a 10 µL aliquot into a clean 2 mL 9-well collection plate 
2. Addition of 25 µL I-B (500 ng/mL).  Addition of 25 µL methanol to all blanks 
3. Vortex mix plate (ca. 1 minute) 
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4. Addition of 80 µL methanol to all wells 
5. Vortex mix plate (ca. 2 minutes) 
6. Centrifuge 2000 g plate for 10 minutes at room temperature 
7. Transfer 40 µL of supernatant to a clean 1.2 mL 96-well collection plate 
8. Dilute with 160 µL 10 mM of ammonium acetate:ammonium hydroxide (100:0.5 
v/v) solution 
9. Vortex mix plate (ca. 2 minutes) 
10. Complete analysis by LC/MS-MS   
 
2.5 Pharmacokinetic analysis. Pharmacokinetic analysis of concentrations of d2-NA 
and NA in blood and plasma was performed using the validated non-
compartmental pharmacokinetic analysis program Phoenix WinNonLin, version 
6.4 (Certara, St Louis, Missouri, USA). 
 
 
3. Results  
No clinical signs were observed to be associated with the IV or PO administration 
of d2-NA or NA at doses up to 120 mg/kg (Table 2) to fifteen animals. A complete list 
of the associated pharmacokinetic parameters determined for each of these dose 
groups are presented in Table 4. For all dose groups, the mean volume of distribution 
was high compared to the blood volume in the rat (ca 54 mL/kg (Davies et al., 1993)), 
suggesting that test compound was distributed into body water or tissues. The mean 
plasma clearance of all groups was lower than liver blood flow in the rat (ca 
3000 mL/h/kg (Davies et al., 1993)) suggesting passive clearance from the systemic 
circulation and some distribution into body tissues and/or saturation of clearance 
mechanisms. The following results were calculated for each group. 
3.1 Control Group A (120 mg/kg NA, IV): 
Although used as a control group in this study, not much is known about the 
pharmacokinetics of NA after IV dosing. Almost all preclinical and clinical in-vivo data 
have resulted from PO dosing regimes. We report here that a mean plasma 
concentration of NA of 168000 ± 9170 ng/mL is observed 0.016 hours post-dose, 
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which suggests a mean plasma C0 of 178000 ±16700 ng/mL.  NA was still detected in 
the plasma of all three animals 8 hours post-dose (32500 ± 1100 ng/mL) but was below 
the LLOQ of 50 ng/mL by 24 hours post-dose. These data are presented in Table 4 
and Figure 1. In comparison with group B, exposure to NA was 1.7 times higher than 
exposure to d2-NA after dosing of d2-NA at the same dose level of 120 mg/kg as judged 
by AUC data, even though Cmax data are consistent (Table 4.). This difference is 
driven by a significantly longer half-life observed for NA (4.0 hours for Group A versus 
2.3 hours for Group B). Our interpretation of this data is that d2-NA may be metabolised 
and cleared more quickly from plasma than NA. 
3.2 Group B (120 mg/kg d2-NA, IV): 
After an IV administration of d2-NA at a nominal dose level of 120 mg/kg, a mean 
plasma concentration of d2-NA of 166000 ± 12700 ng/mL was observed 0.016 hours 
post-dose, which is approximately 2-times higher than for group D where the dose is 
(60 mg/ml) and 6-times higher than for group E (20 mg/ml). This indicates dose 
response proportionality. A mean plasma C0 level of 172000 ± 16700 ng/mL was 
detected which compares well with the C0 of 178000 ±16700 ng/mL of control group 
A (120 mg/kg NA, IV). Increased d2-NA levels were still detected in all three animals 
at 8 hours post-dose but the value falls to below 50 ng/mL in all three animals by 24 
hours post-dose.  
Interestingly, although only d2-NA was dosed in this group, low levels of NA were 
detected in two out of the three animals at the first sampling point (mean 73 ± 63.2 
ng/mL), increasing to a mean Cmax of 4400 ± 229 ng/mL (ca 2.7% of d2-NA) at 8 hours 
post-dose (Figure 3). An estimate of the t½ and corresponding AUC(0- for NA could 
not be determined from a simple analysis of the NA pharmacokinetic profile. 
3.3 Group C (120 mg/kg, d2-NA PO): 
Following PO administration of d2-NA at a nominal dose level of 120 mg/kg, the 
plasma of all animals demonstrated exposure to the agent. A mean maximum (Cmax) 
plasma concentration of 96000 ± 31500 ng/mL was reached within 0.5 to 4 hours 
(median of 0.5 hours). By 24 hours post dose, the mean plasma concentrations of d2-
NA had declined to a baseline value of 21.7 ± 37.6 ng/mL, 0.02% of Cmax. Hence the 
mean terminal elimination half-life is 2.00 hours suggesting rapid elimination, which is 
comparable to that found for group B, after an IV dose at the same initial level. The 
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mean AUC(0-t) was 20100 ± 1190 h.ng/mL, is also comparable to the systemic 
exposure observed after a 120 mg/kg IV dose (group B). 
3.4 Group D (60 mg/kg d2-NA, IV): 
After an IV administration of d2-NA at a nominal dose level of 60 mg/kg, a mean 
plasma concentration of d2-NA of 79400 ± 4540 ng/mL was observed at (Ct), 0.016 
hours post-dose. d2-NA was still detected in all three animals at 8 hours post-dose but 
had been eliminated in two out of three by 24 hours post-dose. The terminal half-life 
(t½) was 2.23 ± 0.78 hours. As for group B, NA was detected in all three animals at the 
first sampling point, albeit at very low concentrations: mean 225 ± 40.9 ng/mL. 
However, the concentration of NA increased to a mean of 3830 ± 97.1 ng/mL (ca 4.8% 
of d2-NA) at 4 hours post-dose. 
3.5 Group E (20 mg/kg d2-NA, IV):  
Following IV administration of d2-NA at a nominal dose level of 20 mg/kg, a mean 
plasma concentration of d2-NA of 27700 ng/mL, was observed at the first sampling 
point (Ct), 0.016 hours (1 minute) post-dose. When extrapolated back to time zero 
(C0), this corresponds to a mean plasma concentration of 28700 ± 657 ng/mL. d2-NA 
again proved to be eliminated in all animals by 24 hours post-dose. The mean areas 
under the plasma concentration time curves, AUC(0-t) and AUC(0- were 34000 ± 
5370 h.ng/mL and 34800 ± 6460 h.ng/mL, respectively, with a corresponding terminal 
half-life (t½) of 0.828 ± 0.175 hours. As now expected, NA was detected in all three 
animals at the first sampling point and a mean maximum concentration of 2310 ± 180 
ng/mL(ca 8% of parent compound) was achieved at ca 2 hours post-dose. These data 
did not lend themselves to t½ or AUC(0- determination. 
4. Discussion 
The dose normalised AUC(0- data suggests that at 60 and 120 mg/kg levels the 
exposure to d2-NA is proportional to the dose administered (Figure 2). The sub-
proportional exposure, in terms of AUC(0- at the lowest dose level, 20 mg/kg, is 
possibly due to concentrations being smaller relative to the animals NA pool, but we 
note they are also close to the limits of quantification, and hence there were fewer 
detectable data points; the corresponding pharmacokinetic parameters are therefore 
less well defined. The measured exposure level after a PO dose of d2-NA was however 
directly comparable to that of IV exposure at 120 mg/kg and this is reflected in the 
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measured bioavailability of 98.7%. Hence, the IV and PO routes should result in similar 
agent response behaviour. In fact, Cmax concentrations of NA after IV administration 
were comparable to those of d2-NA after d2-NA administration. 
NA occurs as a component of a variety of biological systems and as a part of the 
coenzyme nicotinamide adenine dinucleotide (NADH / NAD+): it is crucial to life 
(Belenky et al., 2007). Once ingested, nicotinamide undergoes a series of reactions 
that transform it into NAD, which can then undergo a transformation to form NADP+. 
However, rats and humans can produce NAD+ from the amino acid tryptophan and 
niacin without ingestion of nicotinamide (Williams et al.,2015). As part of our analysis, 
we estimated the endogenous level of NA to be approximately 50 ng/mL in rat plasma 
and set the Lower Limit of Quantification (LLOQ) for our analysis at this level. The 
ULOQ was set at 250,000 ng/ml. 
This study aims to determine the pharmacokinetics of d2-NA after dosing in-vivo in 
comparison to a control group of NA.  However, one of the most interesting findings is 
that dosing of d2-NA elicits a release or production of NA in-vivo, isolated in blood 
plasma of rats from groups B, D and E (Figure 3). A significant level of NA (Cmax 2310 
± 180 ng/mL) was observed 2 hours after dosing d2-NA at 20mg/kg (group E). This is 
approximately 8% of the level of d2-NA dosed. This NA concentration reduced to zero 
after 8 hours and did not fit a normal pharmacokinetic profile. For the 60mg/kg d2-NA 
group (D) the level of NA observed rose to 3830 ± 97.1 ng/mL (4.8% of d2-NA) 4 hours 
post-dose while for a 120 mg/kg dose of d2-NA (group B) a mean Cmax of 4400 ± 229 
ng/mL (2.7% of d2-NA) was found at 8 hours post-dose (Figure 3).  
 Our interpretation of these data is that at all dose levels used in this study d2-NA 
exchanges and partially replaces the ³SRRO´ RI endogenous NA in body tissues, 
resulting in a release of NA into the plasma during the time course of our assay. The 
data presented in Figure 3 shows how the concentrations of NA, which are significantly 
in excess of the estimated endogenous NA levels and LLOQ of 50 ng/mL, vary with 
time after dosing with d2-NA. Endogenous NA, which is replaced by d2-NA and 
released to the plasma, is linked to the response level in terms of Cmax to the levels of 
d2-NA injected. In comparison to the concentration-versus-time plasma levels of d2-
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NA (Figure 2) there is a delay of 2-8 hours to reach Cmax for the released endogenous 
NA (Figure 3) which suggest that exchange with the endogenous pool is slow. The 
shapes of these NA concentration-versus-time profiles are consistent with this slow 
replacement of NA in the endogenous pool by d2-NA followed by simultaneous 
clearance of the excess released endogenous NA. Importantly, the plasma levels of 
NA after dosing d2-NA return to baseline by 24-hrs, indicating the clearance of all 
dosed d2-NA and the released endogenous NA. 
The presence of NA when d2-NA is dosed in rats is not a result of contamination of 
the dose samples or loss of the deuterium label from d2-NA. In a bioanalytical study 
we have demonstrated that the deuterium label of d2-NA is stable in rat blood plasma 
for significantly longer than 24 hours (data not shown). 
5. Conclusions 
Importantly, this study has demonstrated that d2-NA is well tolerated regardless 
of route of administration at the concentrations used (20, 80 and 120 mg/kg 
bodyweight) and that pharmacokinetic parameters of d2-NA are similar after PO and 
IV administration and similar to those obtained for NA after IV dosing. Taken together 
the pharmacokinetic data suggest that there are no significant differences between 
dosing either NA or d2-NA. This is important as it helps us to bridge the large body of 
known clinical data for the use of NA via PO dosing with our intended IV administration 
of hyperpolarized d2-NA as an MRI imaging agent. 
Concerning the significant presence of NA after dosing of d2-NA our conclusion is 
that an endogenous pool of NA is partially replaced by d2-NA in a dose dependent 
fashion (Figure 3). We have also shown that this process is reversible on the timescale 
of our study after a single dose at time zero and hypothesize that newly synthesized 
endogenous NA refills the endogenous cellular or body tissue pool. Both d2-NA and 
the released endogenous NA are completely cleared within 24 hours after IV dosing 
and a normal equilibrium is restored to the pool of endogenous NA.  
This pharmacokinetic study is the first of two in-vivo rat studies we will be 
conducting. It will be followed by a single-dose IV bolus study of d2-NA in rats followed 
by a 14-day recovery period, necropsy and histopathology, to determine the safety 
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toxicity profile of this d2-NA after hyperpolarization and extraction from the SABRE 
catalyst reaction mix. We will use a biphasic separation procedure to do this (modified 
from Manoharan et al., 2019). This toxicity study will be a pivotal preclinical study to 
determine if this d2-NA agent can be progressed clinically in humans as an MRI 
imaging agent of well perfused organs or tissues such as the heart, brain or kidney. 
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Table 1: Agents used for this PK study 
Test Substance Name: 4,6-d2-nicotinamide nicotinamide 
Acronym d2-NA NA 
Chemical Form: Free compound Free compound 
Physical Form: Solid Solid 
Chemical Structure: 
 
 
 
Molecular Formula: C6H4D2N2O C6H6N2O 
Molecular Weight: 124.1 g/mol 122.1 g/mol 
Chemical Purity: 99% 99% 
 
 
 
Table 2: Dose groups for d2-NA and NA 
Dose Group Agent used Dose route Dose level 
Number of 
animals 
   mg/kg Males 
A NA IV 120 3 
B d2-NA IV          120 3 
C d2-NA PO 120 3 
D d2-NA IV 60 3 
E d2-NA IV 20 3 
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Table 3: Mass Spectrometer setup 
 
  Mass Spectrometer     Sciex 6500 
  Ionisation Interface and Temperature   TISP 650°C 
  LC System             Shimadzu Nexera 
  Mobile Phase A 10 mM ammonium acetate: ammonium hydroxide (100:0.5) 
  Mobile Phase B methanol 
  Weak Wash methanol: water (50:50) 
  Strong Wash 2-propanol: methanol: THF: water (25:25:25:25 v/v/v/v) 
  Auxiliary Wash methanol: water (50:50) 
  Injection Volume 20 µL 
  Analytical Column Phenomenex Gemini 3 µm NX-C18, 50 x 2 mm 
  Column Temperature 40°C 
  Flow Rate 0.6 mL/min 
  Sample Temperature  5°C 
 
Gradient 
Profile 
 
Time (min) % Aqueous Phase 
  
0 95 
  
0.2 95 
  
2 2 
  
2.5 2 
  
2.6 95 
  
3.2 95 
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Table 4: Pharmacokinetic parameters 
Dose 
Group 
Cmax t½ AUC(0-t) AUC(0- C0 Vz Cl 
 ng/mL hours h.ng/mL h.ng/mL ng/mL mL/kg mL/h/kg 
A 168000 4.06 573000 774000 178000 911 163 
B 166000 2.33 416000 459000 172000 877 262 
C 96000 2.00 418000 386000 - - - 
D 79400 2.23 196000 197000 82700 963 307 
E 27700 0.83 34000 34800 28700 691 586 
 
Cmax maximum plasma concentration observed 
t½ the terminal elimination phase half-life was determined by linear 
regression of at least three data points (not including Cmax) the terminal 
portion of the log-linear concentration vs time curve. 
AUC(0-t) area under the concentration-time curve calculated from 0-t, where t is 
the time of the last measurable concentration, was calculated by non-
compartmental analysis using the log/linear trapezoidal rule. 
AUC(0- area under the concentration- time curve extrapolated to infinite time was 
calculated by non-compartmental analysis using the log/linear 
trapezoidal rule.  
C0 plasma concentration at time zero following the IV dose was obtained by 
back extrapolation of the first two plasma concentrations. 
Vz volume of distribution based on the terminal phase following IV dosing, 
calculated using the equation: 
)0( fu
 
AUC
DoseV
z
z O  
Cl total body clearance following IV dosing was calculated using the 
equation:  
)0( f
 
AUC
DoseCl  
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Figure 1: Mean Concentrations of NA in the plasma of male rats (n=3) following a 
single IV dose at a nominal dose level of 120 mg/kg (group A) 
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Figure 2: Mean concentrations of d2-NA in the plasma of male rats (n=3) 
following a single IV administration of d2-NA at nominal dose levels of 
20 mg/kg (group E    ), 60 mg/kg (group D     ) and 120 mg/kg (group B    ) 
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Figure 3: Mean concentrations of NA in the plasma of male rats (n=3) following 
a single IV administration of d2-NA at nominal dose levels of 20 mg/kg (group 
E    ), 60 mg/kg (group D    ) and 120 mg/kg (group B    ). Endogenous NA is 
released after intravenous administration of d2-NA. 
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Figure 4: Mean concentrations of d2-NA in the plasma of male rats (n=3) following a 
single PO administration at a nominal dose level of 120 mg/kg (group C) 
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